JAGUAR HEALTH INC. overview

Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Napo's core target patient audiences for Gelclair are head and neck cancer patients and bone marrow transplant patients SAN FRANCISCO, CA / ACCESS Newswire / April 8, 2025 / Jaguar Health, Inc. (...

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 4, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("Jaguar" or the "Company") today announced that, effective April 3, 2025, the Company granted 3,600 restricted stock units (RSUs) to New Employee 1, 3,600 RSUs to New Employee 2, 600 RSUs to New Employee 3, 100 RSUs to New Employee 4, 600 RSUs to New Employee 5, and 600 RSUs to New Employee 6. The RSUs for New Employees 1 and 2 vest over three years, with one-third of the RSUs vesting each year...

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement. Jaguar's president and chief executive officer Lisa Conte, as well as other members of the Company's board of directors and other C-suite and senior executives of Jaguar along with selected institutional and accredited investors (each, an "Investor") entered into securities purchase agreements in...

The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended December 31, 2023 The total net Q4 2024 revenue of approximately $3.5 million for prescription and non-prescription products, including license revenue, increased approximately 13% versus net Q3 2024 revenue of $3.1 million and 53% versus net Q4 2023...

Canalevia ® -CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA In dogs undergoing chemotherapy, as is the case with people undergoing cancer treatment, diarrhea is a highly neglected and unmet medical need SAN FRANCISCO, CA / ACCESS Newswire / March 28, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ), under its Jaguar Animal Health tradename for the veterinary market, today announced the results of a new survey of 27...

The statistically significant responder analysis results for Mytesi ® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium Late-breaker abstract recently submitted to the Multinational Association of Supportive Care in Cancer (MASCC) shows additional significant results for breast cancer subgroup The American Cancer Society expects 316,950 new cases of breast...

Click here to register for Jaguar's March 27 virtual presentation at the Emerging Growth Conference Click here to register for Jaguar's March 31 investor webcast Company plans to file its annual report on March 31, 2025 on Form 10-K for the year ended December 31, 2024 SAN FRANCISCO, CA / ACCESS Newswire / March 26, 2025 / Jaguar Health, Inc . (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, March 27, 2025 at the...

SAN FRANCISCO, CA / ACCESS Newswire / March 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that Jaguar's president and chief executive officer Lisa Conte, three other members of the Company's board of directors, and seven other C-suite and senior executives of Jaguar along with selected institutional and accredited investors (each, an "Investor") entered into securities purchase agreements, pursuant to which the Company will issue up to $3.448 million...